Cyclin-dependent kinase inhibitors and methods of use

A compound represented by Formula (I):

• or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:
• X is —OR, ═O, or —NR1R2;
• R is H or C1-C6 alkyl;
• R1 and R2 are each independently H, C1-C6 alkyl, —C(O)—C1-C6 alkyl, or R1 and R2, together with the nitrogen atom to which they are attached, form a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring optionally comprising one or more additional heteroatoms selected from nitrogen, sulfur, and oxygen;
• u, v, and w together form (i), (ii), or (iii):
• y and z together form (iv) or (v):
• and
• Het is isoquinolinyl, indazolyl, pyridinyl, pyridazinyl, pyrazinyl, benzoquinolinyl, purinyl, pyrrolopyrimidinyl, or quinazolinyl, and optionally substituted with NH2, wherein the compound is not a compound of Formula (A):
• wherein Het is selected from 7-isoquinolinyl, 6-isoquinolinyl, 5-isoquinolinyl, 6-quinolinyl, and 3-pyridyl.